LifeStance (LFST) files Form 144 for proposed sale of 3,759 shares

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 3,759 shares of Common Stock through Morgan Stanley & Co. LLC with an aggregate market value of $20,336.19. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025.

The shares were originally acquired 06/10/2021 in pre-IPO transactions from LifeStance Health Group Inc.; the filer reported acquiring 21,572 shares on that date. The notice states there were no securities sold by the account in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: A small director/insider sale notice: 3,759 shares worth ~$20k, representing an immaterial fraction of outstanding stock.

The Form 144 reports a proposed sale that is modest in size relative to the issuer's ~388.9 million shares outstanding, suggesting limited market impact. The shares were acquired pre-IPO on 06/10/2021 and the proposed broker is Morgan Stanley & Co. LLC. No sales were reported in the prior three months, which may indicate this is a routine liquidity event rather than a pattern of disposals. Documentation includes the standard signatory representation regarding material non-public information.

Corporate Governance Expert

TL;DR: The filing documents a routine insider sale under Rule 144 with no disclosed governance or disclosure issues.

The notice follows Rule 144 disclosure requirements: it identifies the broker, the class and quantity of shares, acquisition details (pre-IPO on 06/10/2021), and affirms no knowledge of undisclosed material adverse information. Given the small size of the proposed sale relative to total shares outstanding, this filing alone does not raise immediate governance or disclosure red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	3759	20336.19	388936394	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/10/2021	Pre-IPO Transactions	LifeStance Health Group Inc.			21572	06/10/2021	Equity interests in the Issuer were purchased pre-IPO.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the LFST Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 3,759 common shares via Morgan Stanley & Co. LLC with an aggregate market value of $20,336.19 and an approximate sale date of 08/18/2025.

When and how were the securities being sold originally acquired?

The securities were acquired on 06/10/2021 in pre-IPO transactions from LifeStance Health Group Inc., totaling 21,572 shares acquired on that date.

Does the Form 144 report any sales in the past three months for LFST?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

How material is the proposed sale relative to LFST's outstanding shares?

The proposed sale of 3,759 shares is a very small fraction of the reported 388,936,394 shares outstanding, indicating limited market impact based on this filing alone.

Who is the broker listed for the transaction in the Form 144?

The broker named in the filing is Morgan Stanley & Co. LLC, 1585 Broadway, New York, NY 10036.